乳腺癌患者报告疲劳的长期纵向模式:基于组的轨迹分析
该研究基于2012至2015年治疗的大规模全国前瞻性临床研究(CANcer TOxicity,NCT01993498),对I-III期乳腺癌患者诊断时及诊断后1、2、4年的疲劳进行纵向分析。采用基于组的轨迹模型识别出严重整体疲劳的三个轨迹组:高风险组占21%,恶化组占19%,低风险组占60%,不同疲劳维度聚为不同轨迹组且受不同因素影响。
要点
- 严重整体疲劳识别出三个轨迹组:高风险组21%、恶化组19%、低风险组60%。
- 高风险组严重整体疲劳风险从诊断时94.8%降至第4年64.6%。
- 恶化组严重整体疲劳风险从诊断时13.8%升至第4年64.5%。
核心结论
- 研究结果凸显癌症相关疲劳的多维性及其危险因素的复杂性,有助于识别严重疲劳高风险患者并为个体化干预提供信息。
研究设计与样本
- 基于大规模全国前瞻性临床研究(CANcer TOxicity,NCT01993498)的详细纵向分析,纳入2012至2015年治疗的I-III期乳腺癌患者。
- 疲劳在诊断时及诊断后第1、2、4年评估,基线临床、社会人口学、行为、肿瘤及治疗相关特征可用。
- 采用基于组的轨迹模型迭代估计识别疲劳轨迹及轨迹组归属的危险因素。
主要发现
- 严重整体疲劳(n=4,173)识别出三个轨迹组:高风险组占21%,诊断时严重整体疲劳风险估计为94.8%(95% CI,86.6至100.0),第4年为64.6%(95% CI,59.2至70.1)。
- 恶化组占19%,诊断时严重整体疲劳风险估计为13.8%(95% CI,6.7至20.9),第4年为64.5%(95% CI,57.3至71.8)。
- 低风险组占60%,诊断时严重整体疲劳风险估计为3.6%(95% CI,2.5至4.7),第4年为9.6%(95% CI,7.5至11.7)。
- 疲劳的不同维度聚为不同于严重整体疲劳所识别的轨迹组,受社会人口学、临床及治疗相关因素影响不同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fatigue is recognized as one of the most burdensome and long-lasting adverse effects of cancer and cancer treatment. We aimed to characterize long-term fatigue trajectories among breast cancer survivors. METHODS: We performed a detailed longitudinal analysis of fatigue using a large ongoing national prospective clinical study (CANcer TOxicity, ClinicalTrials.gov identifier: NCT01993498) of patients with stage I-III breast cancer treated from 2012 to 2015. Fatigue was assessed at diagnosis and year 1, 2, and 4 postdiagnosis. Baseline clinical, sociodemographic, behavioral, tumor-related, and treatment-related characteristics were available. Trajectories of fatigue and risk factors of trajectory-group membership were identified by iterative estimates of group-based trajectory models. RESULTS: Three trajectory groups were identified for severe global fatigue (n = 4,173). Twenty-one percent of patients were in the high-risk group, having risk estimates of severe global fatigue of 94.8% (95% CI, 86.6 to 100.0) at diagnosis and 64.6% (95% CI, 59.2 to 70.1) at year 4; 19% of patients clustered in the deteriorating group with risk estimates of severe global fatigue of 13.8% (95% CI, 6.7 to 20.9) at diagnosis and 64.5% (95% CI, 57.3 to 71.8) at year 4; 60% were in the low-risk group with risk estimates of 3.6% (95% CI, 2.5 to 4.7) at diagnosis and 9.6% (95% CI, 7.5 to 11.7) at year 4. The distinct dimensions of fatigue clustered in different trajectory groups than those identified by severe global fatigue, being differentially affected by sociodemographic, clinical, and treatment-related factors. CONCLUSION: Our findings highlight the multidimensional nature of cancer-related fatigue and the complexity of its risk factors. This study helps to identify patients with increased risk of severe fatigue and to inform personalized interventions to ameliorate this problem.
引用
- Vaz-Luis I, Di Meglio A, Havas J, et al. Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. J Clin Oncol. 2022. PMID: 35290073. doi:10.1200/JCO.21.01958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。